循环类药物研究的进展:从生物活性到基于循环类药物的治疗方法
Ankita Grover1, Sawraj Singh1, Sonal Sindhu2
1Department of Microbiology, Maharshi Dayanand University, Rohtak, Haryana, 124001, India.
Molecular diversity
|January 25, 2025
概括
环化物是稳定的植物,具有独特的循环囊结 (CCK) 结构. 工程技术的进步正在释放它们在农业和医学方面的潜力,克服生产和交付方面的挑战.
科学领域:
- 植物生物化学和分子生物学
- 酸科学是一种科学.
- 生物技术是生物技术.
背景情况:
- 环类是植物衍生的循环,其特点是保存的循环囊结 (CCK) 图案.
- 在各种植物家族中已知有超过750种环状蛋白,表现出多种生物活性,包括抗微生物,抗病毒和杀虫剂特性.
- 它们的作用机制涉及通过疏水面破坏膜,突出了结构-活动关系的重要性.
研究的目的:
- 审查环旋的多样性,生物活性和结构-活性关系.
- 探索循环体工程的进步,以克服发展挑战.
- 强调环酸在医疗和生物技术应用中的潜力.
主要方法:
- 文献综述和综合现有关于环旋的研究.
- 分析环胺结构,功能和生物活性数据.
- 检查当前和新兴的环旋工程策略.
主要成果:
- 环氧化物由于其稳定性和生物活性,具有显著的治疗和农业潜力.
- 结构-活性关系对于理解和优化环类功能至关重要.
- 工程方法,如接种,结合和异质生产,显示出提高循环的功效的前景.
结论:
- 环化物是药物开发和农业应用的一个有前途的分子类别.
- 通过工程克服生产和药物动力学方面的挑战是实现其全部潜力的关键.
- 对循环基因工程的进一步研究将推动基于的生物制剂的创新.
更多相关视频
相关概念视频
Positive Regulator Molecules
5.3K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.3K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Structure-Activity Relationships and Drug Design
493
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
493
Drug Discovery: Overview
7.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.4K
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K


